Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27043895 | 0.87 | RIPK1 (0.44) | RIPK1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13715995 | 0.86 | CA12 (0.40) | RIPK1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12741115 | 0.83 | CA12 (0.34) | RIPK1CA12CA2CA9TSHR | |
| SCHEMBL24193686 | 0.82 | DNM1 (0.44) | — | |
| SCHEMBL20349291 | 0.82 | DNM1 (0.44) | — | |
| SCHEMBL21896014 | 0.81 | RIPK1 (0.50) | RIPK1 | |
| SCHEMBL16804491 | 0.81 | MLYCD (0.34) | RIPK1MEN1KMT2ACA12CA2 | |
| SCHEMBL1712608 | 0.80 | MAPT (0.46) | RIPK1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8137111 | 0.80 | RIPK1 (0.41) | RIPK1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1712606 | 0.80 | RIPK1 (0.37) | RIPK1MEN1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230242486-A1 | PYRIDINYL MORPHOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230159465-A1 | IMMUNOMODULATOR | HITGEN INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159465-A1 | IMMUNOMODULATOR | HITGEN INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-10945435-B2 | Imidazopyrimidine derivatives with sulfur containing phenyl and pyridyl substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20160022829-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-8227492-B2 | Sulfoxamine derivatives as factor Xa inhibitors | CADILA HEALTHCARE LIMITED (IN) | 2012-07-24 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110065717-A1 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2011-03-17 | — | — | US | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10945435-B2 | Imidazopyrimidine derivatives with sulfur containing phenyl and pyridyl substituents | PNPO, DDT, TH | RIPK1 3789/4885MEN1 3081/4885CYP3A4 9/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | RIPK1 448/4885MEN1 1427/4885CYP3A4 3450/4885 |
| US-20230159465-A1 | IMMUNOMODULATOR | IL2, IL17A, IL2RA | RIPK1 2674/4885MEN1 3926/4885CYP3A4 1377/4885 |
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | RIPK1 2016/4885MEN1 3812/4885CYP3A4 4598/4885 |
| US-20230242486-A1 | PYRIDINYL MORPHOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HTR2C, HTR3D, HTR5A | RIPK1 3426/4885MEN1 753/4885CYP3A4 938/4885 |
| US-20230227437-A1 | IMMUNOMODULATOR | IL17A, IL2, IL2RA | RIPK1 2561/4885MEN1 3795/4885CYP3A4 826/4885 |
| US-20110065717-A1 | SULFOXIMINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F12, F2 | RIPK1 2313/4885MEN1 1863/4885CYP3A4 376/4885 |
| US-20160022829-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | LGMN, TLL1, TEK | RIPK1 2807/4885MEN1 3406/4885CYP3A4 4858/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | RIPK1 1749/4885MEN1 4042/4885CYP3A4 703/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | RIPK1 2586/4885MEN1 4876/4885CYP3A4 436/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | RIPK1 2016/4885MEN1 3812/4885CYP3A4 4598/4885 |
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | CNR1, CNR2, OPRL1 | RIPK1 1479/4885MEN1 2532/4885CYP3A4 695/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | RIPK1 2016/4885MEN1 3812/4885CYP3A4 4598/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | RIPK1 1868/4885MEN1 4026/4885CYP3A4 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.